Supplementary
. The ROC plots of ten distinct conformations of GLP-1R from conformation sampling.
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Supplementary Figure S3 . VIPR peptide agonist mediated VIPR signaling and VIPR peptide antagonist mediated VIPR inhibition in HEK293 cells expressing the cAMP response elementluciferase reporter. HEK293-CREB luciferase cells were treated with different concentrations of VIPR peptide agonist in the absence or presence of VIPR peptide antagonist. VIPR activation was measured and plotted as the amount of luminescence produced, which was normalized by protein concentration. The readings for VIPR peptide agonist alone are plotted as ( VIPR peptide alone). The combination of VIPR peptide agonist and antagonist is represented as ( VIPR agonist + VIPR antagonist 1.12µM) and ( VIPR agonist + VIPR antagonist 5.6 µM). The data indicated that VIPR antagonist at 5.6 µM is effective to deactivate VIPR signaling by VIPR peptide agonist. Data showed that in the presence of VIPR in HEK293 and VIPR activity could be effectively inhibited by VIPR antagonist. This assay can be used to evaluate the non-specific contribution of VIPR in response to M_4. Data is representative of three independent experiments with at least three technical replicates for each treatment conditions and error bars for each concentration were plotted as SEM (n=3). Statistical analysis was done using 2-way ANOVA (****p<0.0001). The statistical comparison was done with respect to the corresponding normalized luminescence reading of VIPR activation by VIPR peptide agonist alone. V P A C a g o n is t o n ly V P A C a g o n is t + V P A C a n ta g o n is t ( 1 .1 2 µ M ) V P A C a g o n is t + V P A C a n ta g o n is t ( 5 .6 µ M ) **** **** ****
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